Study ID | Sex | Age at T0 | Time T0–T1 (days) | T0–T1 ompA genovars | T0–T1 MLST | Treatment T0 index_partner | No. of recent partners T0 and T1* | Possible explanation repeat infection at T1† | |
---|---|---|---|---|---|---|---|---|---|
Concordant C trachomatis genotypes | |||||||||
1 | F | 19 | 197 | D_D | 12a_12a | ?_no | 2 | ? | R or P |
2 | F | 29 | 237 | D_D | 365_365 | ?_? | ? | ? | R or P |
3 | F | 19 | 215 | D_D | 360_360 | yes_yes | 1 | ? | TF |
4 | M | 25 | 357 | F_F | 110_110 | yes_yes | 1 | ? | TF |
5 | F | 23 | 200 | E_E | 364_364 | ?_? | 5 | ? | R or P |
6 | M | 20 | 243 | I_I | 25b_25b | ?_? | 3 | ? | R or P |
7 | F | 22 | 169 | E_E | 16_16 | yes_yes | 1 | 1_1 | TF |
8 | F | 31 | 167 | F_F | 62b_62b | yes_ ? | 1 | 1_1 | TF or R |
9 | F | 24 | 153 | E_E | 59_59 | yes_yes | 2 | 3_1 | TF |
10 | M | 23 | 211 | E_E | 69_69 | yes_yes | 1 | 1_1 | TF |
Discordant single locus variant C trachomatis genotypes | |||||||||
11 | F | 19 | 194 | E_E | 356_357 | yes_? | 3 | 2_1 | N |
12 | F | 22 | 161 | E_E | 366_3. | yes_? | 4 | ? | N |
13 | F | 19 | 147 | F_F | 90_12d | yes_NA‡ | 1 | 3_0 | N |
14 | F | 22 | 203 | E_E | 87_3 | ?_? | 4 | ? | N |
Discordant multilocus variant C trachomatis genotypes | |||||||||
15 | F | 23 | 193 | K_E | 34b_56a | yes_yes | 3 | ? | N |
16 | M | 23 | 196 | E_E | 326b_362 | ?_? | 3 | ? | N |
17 | M | 28 | 202 | D_E | 361_56a | ?_? | ? | ? | N |
18 | F | 17 | 193 | F_J | 12d_136b | ?_? | 3 | ? | N |
19 | F | 25 | 195 | E_J | 86_264 | yes_no | 9 | 8_2 | N |
20 | F | 26 | 204 | F_E | 12d_56a | yes_yes | 1 | 1_1 | N |
21 | F | 19 | 226 | E_J | 56a_100b | ?_? | 4 | ? | N |
22 | F | 28 | 197 | E_F | 358_12d | yes_ NA | 9 | ? | N |
23 | F | 17 | 190 | D_F | 359_12d | yes_NA | 3 | 2_0 | N |
24 | F | 28 | 153 | F_E | 12d_56a | yes_NA | 2 | 3_0 | N |
25 | F | 27 | 156 | J_F | 363_110 | no_? | 2 | 1_1 | N |
26 | F | 20 | 167 | G_E | 265_3. | yes_NA | 20 | 3_0 | N |
27 | M | 19 | 182 | K_G | 32_128a | yes_NA | 6 | 3_0 | N |
Cases 7–9, 11, 12, 13 and 23–27 pertained to the CRI study and all others to the CSI study.
*Number of partners in the 6 months before T0 respectively T1; second number after underscore at T1: number of partners among those who were already partners before T0.
†Possible outcome at T1: R, recurrent infection by same partner; P, persistent infection without treatment.
‡NA, not applicable: no sex after T0 treatment with regular partner.
CRI, Chlamydia Retest Implementation; CSI, Chlamydia Screening Implementation; MLST, multilocus sequence typing; TF, treatment failure; N, new infection by same or new partner.